Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.

Trial Profile

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal infections
  • Focus Adverse reactions
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 25 Sep 2016 Status changed from recruiting to completed.
    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top